These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36316998)

  • 1. Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib.
    Owji S; Caldas SA; Ungar B
    J Asthma Allergy; 2022; 15():1527-1537. PubMed ID: 36316998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib cream for the short-term treatment of mild-moderate atopic dermatitis.
    Krajewski PK; Szepietowski JC
    Expert Rev Clin Immunol; 2023 Apr; 19(4):349-356. PubMed ID: 36542765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
    J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives.
    Eichenfield LF; Liu J; Marwaha S; Piercy J; Sturm D; Anderson P
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):685-696. PubMed ID: 38453811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
    Hu W; Thornton M; Livingston RA
    Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
    Zhang L; Du D; Wang L; Guo L; Jiang X
    J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
    Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
    Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
    Smith P; Yao W; Shepard S; Covington M; Lee J; Lofland J; Naim A; Sheth T; Parikh B; Yeleswaram S
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results.
    Szalus K; Trzeciak M; Nowicki RJ
    Microorganisms; 2020 Nov; 8(11):. PubMed ID: 33172122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
    Zhang L; Wang L; Jiang X
    Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atopic dermatitis: a review of topical treatment options.
    Simpson EL
    Curr Med Res Opin; 2010 Mar; 26(3):633-40. PubMed ID: 20070141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 1: Ruxolitinib.
    Mancuso-Stewart E; DiRuggiero M; DiRuggiero D; Zirwas M
    Skinmed; 2023; 21(2):93-98. PubMed ID: 37158346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of atopic eczema.
    Werfel T; Claes C; Kulp W; Greiner W; von der Schulenburg JM
    GMS Health Technol Assess; 2006 Oct; 2():Doc19. PubMed ID: 21289970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.